Follow the Freenome, Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Market capitalisation: €2bn. The latest transaction was reported on 29 July 2026 (C). Among the most active insiders: RA CAPITAL MANAGEMENT, L.P.. The full history is free.
14
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Freenome, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$56.73.
19Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
336,965 shares@ US$10.006.4% of flowCommon StockSEC:0001231919-26-000783:6
14 of 14 declarations
About Freenome, Inc.
Freenome, Inc. is a biotechnology company that uses artificial intelligence to detect cancer at an early stage. It focuses on developing blood-based screening tests to improve patient outcomes.